Skip to content

Biogen downgrades hit sector

March 16, 2017

Leerink’s Geoffrey Porges pointed out in a note the meaningful catalysts that had been expected for Biogen Inc BIIB 4.67% “have passed, mostly positively, and generated some value for investors; the incremental catalysts from here look relatively limited.”

The analyst downgraded the company from Outperform to Market Perform, while lowering the price target from $305 to $300.

Catalysts Waning

“Our downgrade is based on a slower than expected ramp for Spinraza, and the completion of the series of important catalysts that have evolved over the last few months,” Porges explained.

The analyst lowered the revenue estimate for 2017 by 1 percent, with the revenue estimate for later years being lowered by 2-3 percent.

“These adjusted forecasts are now more or less in line with consensus, and in fact consensus expectations for Spinraza have also been reduced recently,” Porges stated, while adding, “We are not particularly positive about the other programs in Biogen’s late stage pipeline such as BIIB074, BIIB059, STX100 and opicinumab (antiLINGO).”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: